EGFR-Mutated Advanced NSCLC: Enhancing Treatment Strategies and Patient Care With Novel Therapies : Episode 3
Clinical Decision-Making and Sequencing Strategies in EGFR-Mutated NSCLC
Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs) vs infusion or subcutaneous therapies, and Dr Scott addressing approaches to sequencing treatments, shared decision-making, and the role of resistance mechanisms and biopsy in guiding therapy decisions for EGFR-mutated advanced non–small cell lung cancer (NSCLC).
Video content above is prompted by the following:
- How do the various EGFR-targeted therapies differ in terms of administration protocols and the strategies employed for effective patient management?
- How do you tailor nursing interventions for patients on oral TKIs vs those receiving infusion or subcutaneous therapies, especially in managing adverse effects and ensuring adherence?
- What strategies do you employ to facilitate open communication with patients about what to expect during their treatment and to address their concerns effectively?
- How do you approach the sequencing of therapies across multiple lines of treatment in EGFR-mutated NSCLC? How do you approach shared decision-making and patient education when discussing treatment options for EGFR-mutated NSCLC?
- What factors influence your decision-making when moving from one line of therapy to the next?
- How do resistance mechanisms impact your sequencing strategy, and what role does biopsy play in guiding these decisions?
Recent Videos
Related Content
